The potential role of tomudex in the treatment of advanced colorectal cancer

Research output: Contribution to journalArticle


Aims and Background: The quinazoline folate analog thymidylate synthase inhibitor, Tomudex, is about to enter the Italian pharmaceutical market. Its place among the therapeutic options for advanced colorectal cancer is discussed. Methods: The pros and cons of currently available chemotherapeutic regimens are briefly described with special attention to patient's and tumor's determinants of treatment outcome. The mechanism of action and the results of phase I, II and III studies of Tomudex are reviewed. Results: Not all patients need to be treated. Guidelines are given in this respect. Tomudex at the dose of 3 mg/m2 given i.v. every three weeks has antitumor activity similar to that of currently available regimens, with a favorable toxicity profile. Conclusions: Current research approaches are unlikely to dramatically improve the treatment outcome of this disease in the near future. What can reasonably be expected is less toxicity and more convenient routes and schedules of drug administration that may translate into better quality of life for our patients. Tomudex has been devised along these lines.

Original languageEnglish
Pages (from-to)576-580
Number of pages5
Issue number2
Publication statusPublished - Mar 1997


  • Colorectal cancer
  • Tomudex

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'The potential role of tomudex in the treatment of advanced colorectal cancer'. Together they form a unique fingerprint.

  • Cite this